Back to Journals » OncoTargets and Therapy » Volume 15

Curcumin Potentiates the Potent Antitumor Activity of ACNU Against Glioblastoma by Suppressing the PI3K/AKT and NF-κB/COX-2 Signaling Pathways [Retraction]

Authors Zhao J, Zhu J, Lv X, Xing J , Liu S, Chen C, Xu Y

Received 30 November 2022

Accepted for publication 30 November 2022

Published 2 December 2022 Volume 2022:15 Pages 1479—1480

DOI https://doi.org/10.2147/OTT.S399704



Zhao J, Zhu J, Lv X, et al. Onco Targets Ther. 2017;10:5471–5482.

The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 3C. Specifically,

  • Figure 3C, DMSO appears to have been duplicated with the same image for Figure 3C, ACNU.

The authors responded to our queries and explained that the image duplication in Figure 3 was due to image misplacement during preparation of the figure. The authors were asked to provide original data that would adequately verify the reported findings, however the authors explained that some of the original data had been lost and the remaining data was not satisfactory. The Editor determined that the reported findings were unreliable and requested to retract the article. The authors agreed with this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.